1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Cadence Pharmaceuticals,'s 1-Year ROIIC % for the quarter that ended in Dec. 2013 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cadence Pharmaceuticals,'s 1-Year ROIIC % or its related term are showing as below:
FRA:QEW's 1-Year ROIIC % is not ranked *
in the Biotechnology industry.
Industry Median: -4.26 * Ranked among companies with meaningful 1-Year ROIIC % only.
Cadence Pharmaceuticals, 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cadence Pharmaceuticals,'s 1-Year ROIIC %
For the Biotechnology subindustry, Cadence Pharmaceuticals,'s 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cadence Pharmaceuticals,'s 1-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cadence Pharmaceuticals,'s 1-Year ROIIC % falls into.
Cadence Pharmaceuticals,'s 1-Year ROIIC % for the quarter that ended in Dec. 2013 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -20.107 (Dec. 2013) - -58.426 (Dec. 2012) )
/
( 17.295 (Dec. 2013) - 18.4 (Dec. 2012) )
=
38.319
/
-1.105
=
-3,467.78%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cadence Pharmaceuticals, 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cadence Pharmaceuticals, (FRA:QEW) Business Description
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:QEW has been successfully added to your 